JP6263773B2 - 水溶性膜タンパク質およびその調製および使用方法 - Google Patents
水溶性膜タンパク質およびその調製および使用方法 Download PDFInfo
- Publication number
- JP6263773B2 JP6263773B2 JP2013555565A JP2013555565A JP6263773B2 JP 6263773 B2 JP6263773 B2 JP 6263773B2 JP 2013555565 A JP2013555565 A JP 2013555565A JP 2013555565 A JP2013555565 A JP 2013555565A JP 6263773 B2 JP6263773 B2 JP 6263773B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- gpcr
- variant
- receptors
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 29
- 108010052285 Membrane Proteins Proteins 0.000 title description 45
- 238000002360 preparation method Methods 0.000 title description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 36
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 34
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 32
- 108020003175 receptors Proteins 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 239000003446 ligand Substances 0.000 claims description 26
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 26
- 239000004473 Threonine Substances 0.000 claims description 23
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 23
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 22
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 19
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 229960000310 isoleucine Drugs 0.000 claims description 15
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 15
- 102000009410 Chemokine receptor Human genes 0.000 claims description 13
- 108050000299 Chemokine receptor Proteins 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- 102000002020 Protease-activated receptors Human genes 0.000 claims description 12
- 108050009310 Protease-activated receptors Proteins 0.000 claims description 12
- 102000000033 Purinergic Receptors Human genes 0.000 claims description 12
- 108010080192 Purinergic Receptors Proteins 0.000 claims description 12
- 102000011923 Thyrotropin Human genes 0.000 claims description 12
- 108010061174 Thyrotropin Proteins 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000001165 hydrophobic group Chemical group 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 8
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 8
- -1 GPCR-30 Proteins 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 102000009346 Adenosine receptors Human genes 0.000 claims description 6
- 108050000203 Adenosine receptors Proteins 0.000 claims description 6
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 6
- 108010073466 Bombesin Receptors Proteins 0.000 claims description 6
- 102000010183 Bradykinin receptor Human genes 0.000 claims description 6
- 108050001736 Bradykinin receptor Proteins 0.000 claims description 6
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims description 6
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims description 6
- 102000015554 Dopamine receptor Human genes 0.000 claims description 6
- 108050004812 Dopamine receptor Proteins 0.000 claims description 6
- 108050009340 Endothelin Proteins 0.000 claims description 6
- 102000002045 Endothelin Human genes 0.000 claims description 6
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 claims description 6
- 102000011392 Galanin receptor Human genes 0.000 claims description 6
- 108050001605 Galanin receptor Proteins 0.000 claims description 6
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 claims description 6
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 6
- 102000005157 Somatostatin Human genes 0.000 claims description 6
- 108010056088 Somatostatin Proteins 0.000 claims description 6
- 108010072901 Tachykinin Receptors Proteins 0.000 claims description 6
- 102000007124 Tachykinin Receptors Human genes 0.000 claims description 6
- 229950006323 angiotensin ii Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 229940076279 serotonin Drugs 0.000 claims description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 6
- 229960000553 somatostatin Drugs 0.000 claims description 6
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 6
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 5
- 102000011652 Formyl peptide receptors Human genes 0.000 claims description 5
- 108010076288 Formyl peptide receptors Proteins 0.000 claims description 5
- 102000018899 Glutamate Receptors Human genes 0.000 claims description 5
- 108010027915 Glutamate Receptors Proteins 0.000 claims description 5
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 5
- 230000005660 hydrophilic surface Effects 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- 101800001982 Cholecystokinin Proteins 0.000 claims description 4
- 102100025841 Cholecystokinin Human genes 0.000 claims description 4
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 4
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 4
- 229940107137 cholecystokinin Drugs 0.000 claims description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 4
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 108050006947 CXC Chemokine Proteins 0.000 claims 1
- 102000019388 CXC chemokine Human genes 0.000 claims 1
- 108091008928 CXC chemokine receptors Proteins 0.000 claims 1
- 102000054900 CXCR Receptors Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 claims 1
- 102000012547 Olfactory receptors Human genes 0.000 description 52
- 108050002069 Olfactory receptors Proteins 0.000 description 52
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 32
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 31
- 102000018697 Membrane Proteins Human genes 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 239000003205 fragrance Substances 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000002983 circular dichroism Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 5
- 102400000345 Angiotensin-2 Human genes 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 5
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000009460 calcium influx Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001768 microscale thermophoresis Methods 0.000 description 5
- 102000017953 prostanoid receptors Human genes 0.000 description 5
- 108050007059 prostanoid receptors Proteins 0.000 description 5
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BETUMLXGYDBOLV-UHFFFAOYSA-O 2-[hydroxy(tetradecoxy)phosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C BETUMLXGYDBOLV-UHFFFAOYSA-O 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 1
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Description
本出願は、2011年2月23日に出願された米国特許仮出願第61/445,740号の恩典を主張する。上記出願(複数可)の教示は全て、参照により本明細書に組み込まれる。
a.PQRALQFFQSLQAYVQTLTENIQTITAI R(配列番号:3)
b.M YYFLANMSFYLETWYTTVTTPKMQAGYI(配列番号:4)
c.CMTQLYFFQGLGCTECTLLAVMAYDRYVA TC(配列番号:5)
d.RQCVQMAAGSWAGGFGTSMTVKVYQ(配列番号:6)
e.LTDFILAIFILLGPLSVTGASYMAITGAV(配列番号:7)
f.HKAFSTCASHLTTVITYYAAS IYTY(配列番号:8)
g.TNKLVSVLYAVIVPLLNPIIYCLRN(配列番号:9)。
1793-1798; Zaitseva, et al. (1997) Nat Med 3: 1369-1375; Sanchez, et al. (1997)
J Biol Chem 272: 27529-27531)。Tストロマ細胞由来因子1(SDF−1)は、CXCR4と特異的に相互作用するケモカインである。SDF−1がCXCR4に結合すると、CXCR4はGαiタンパク質媒介シグナル伝達を活性化し(百日咳毒素感受性)(Chen, et al. (1998) Mol Pharmacol 53: 177-181)、これには下流キナーゼ経路、例えばリンパ球、巨核球、および造血幹細胞における、Ras/MAPキナーゼおよびホスファチジルイノシトール3−キナーゼ(PI3K)/Aktが含まれる(Bleul, et al. (1996) Nature 382: 829-833; Deng, et al. (1997)
Nature 388: 296-300; Kijowski, et al. (2001) Stem Cells 19: 453-466; Majka, et
al. (2001) Folia. Histochem. Cytobiol. 39: 235-244; Sotsios, et al. (1999) J.
Immunol. 163: 5954-5963; Vlahakis, et al. (2002) J. Immunol. 169: 5546-5554)。ヒトリンパ節が移植されたマウスでは、SDF−1は、移植リンパ節へのCXCR4陽性細胞移動を誘発する(Blades, et al. (2002) J. Immunol. 168: 4308-4317)。
537-549)。様々な乳癌患者から収集した試料では、Mullerら(Muller, et al. (2001) Nature 410: 50-56)は、CXCR4発現レベルは、正常な乳腺または上皮細胞と比較して原発腫瘍において高くなることを見出した。さらに、CXCR4抗体治療は、全てリンパ節および肺へ転移した対照アイソタイプと比較すると、局所リンパ節への転移を阻害することが示されている(Muller, et al. (2001))。そのようなものとして、デコイ療法モデルは、CXCR4媒介疾患および障害を治療するのに好適である。
Reviews 28: 97-119, 1997。本明細書で記載される組成物および薬理学的作用物質は、蓄積注射またはインプラント調製物の形態で投与することができ、これらは、活性成分の持続またはパルス放出を可能にするような様式で製剤化させることができる。
Biochem. Biophys. Acta 1368: 201-15, 1998]。
実施例1:嗅覚受容体のリガンド結合特性の系統的分析
生化学、生物物理および構造解析のために、Q(グルタミン)T(スレオニン)Y(チロシン)QTY置換を使用して、不水溶性嗅覚受容体を水溶性のものに変換する。我々の特定の目的は下記である:
1)7回膜貫通α−へリックス疎水性残基ロイシン(L)、イソロイシン(I)、バリン(V)、およびフェニルアラニン(F)を親水性残基グルタミン(Q)、スレオニン(T)およびチロシン(Y)に体系的に変更させるために、QTY(グルタミン、スレオニンおよびチロシン)置換方法を使用すること。この方法は、タンパク質を不水溶性嗅覚受容体から水溶性のものに変換する。
2)市販の無細胞インビトロ翻訳系(Invitrogen and Qiagen)を用いて、ミリグラム量の天然およびバイオ工学処理嗅覚受容体を生成および精製すること。
3)円二色性(CD)を用いて精製嗅覚受容体の二次構造を決定すること。
4)マイクロスケール熱泳動を用いて、天然およびバイオ工学処理嗅覚受容体変異体の結合親和性を決定すること。
5)天然および変異OR遺伝子をHEK293細胞にトランスフェクトし、およびカルシウム流入アッセイを使用して、天然および変異嗅覚受容体の匂い物質活性化を測定すること。これらの測定は、マイクロスケール熱泳動結合データを細胞内の機能的応答に相関させる。
6)匂い物質の有無および界面活性剤の有無における結晶化条件のために、天然およびバイオ工学処理嗅覚受容体を体系的にスクリーニングすること。
QTY置換を使用して、可溶性7−へリックス束嗅覚受容体mOR103−15を設計すること。我々の研究の革新は、不水溶性嗅覚受容体mORI03−15を、約10.5%特異残基変更(36aa/340aa)を有する水溶性のものに変換することである。我々は、通常、親水性面に面するα−へリックス位置b、c、fの重要な残基を体系的におよび選択的に変更させ、一方、α−へリックス位置a、d、e、gの疎水性残基を維持した。我々の合成生物学設計方法は、一般的であり、他の嗅覚受容体およびGタンパク質共役型受容体の研究に広く適用可能である。この戦略は、嗅覚受容体、ならびに追加のGPCRおよび他の膜タンパク質を結晶化する障害を克服する可能性を有する。配列の溶解度を変更する我々の設計は、ヘリカルホイールのb、c、f位置に焦点を当てているが、配列の他の部分へのいくつかのさらなる変更が、ペプチド、ポリペプチドまたはタンパク質の機能または構造に著しく影響せずに可能である。例えば保存的変異が可能である。
1)QTY置換を使用して、水溶性7−へリックス束嗅覚受容体mOR103−15を設計すること。我々は、合成生物学方法を使用して不水溶性嗅覚受容体を、約10.5%の残基変更(36aa/340aa)を有する水溶性のものに変換した(図1−3)。我々は、α−へリックス位置b、c、f(通常、親水性面を形成する)の重要な残基を体系的および選択的に変更させたが、α−へリックス位置a、d、e、gの疎水性残基を維持した(図1)。我々の合成生物学設計方法は、本来一般的であり、よって、他の嗅覚受容体および他のGタンパク質共役型受容体(GPCR)の研究に広く適用可能である。この単純な戦略は、変換された水溶性膜タンパク質が生物学的に機能的なままである場合、嗅覚受容体、GPCR、および他の膜タンパク質の構造研究の障害を部分的に克服し得る。
ヒトCXCR4および、無細胞生成から得られ、アフィニティビーズを用いて精製された我々のCXCR4 QTYタンパク質を、Biacore 2000機器において1D4抗体(Ab)が固定されたBiacore CM5チップ上の異なるフローセル中に捕獲させた。異なる濃度のSDF1α、hCXCR4受容体に対する天然リガンドを、表面に注入し、受容体と相互作用させた。
Biacore CM5チップを、1−エチル−3−[3−ジメチルアミノプロピル]カルボジイミド塩酸塩およびN−ヒドロキシスクシンイミドを用いて、製造者のプロトコルに従い活性化し、その後、フローセル2−4に70μg/mlで、5μl/分の1D4 Abを7分注射し、続いて、4フローセルの全てにおいて表面を短いエタノールアミンパルスで非活性化した。1D4 Abの固定レベルは8000−25000反応単位(RU)の範囲である。
CXCR4およびCXCR4 QTY変異体を、CM5チップ上の1D4 Abにより、0.1mg/ml試料のタンパク質を単一のフローセルに5μl/分で15分間、両方の試料および0.2%Fos−Choline−14界面活性剤を含む泳動用緩衝液と共に注入することにより、捕獲させる。受容体は800−3000RUのレベルまで捕獲された。
SDF1αを全てのフローセル上に注入し、両方の受容体と相互作用させ、フローセル1つを、固定タンパク質を有さない参照セルとして使用する。注入は、0、7.8nM、15.6nM、31.25nM、62.5nM、125nM、250nM、500nM、1μMで、3通り、20μl/分で2分間実施し、15分の待ち時間を使用して解離させた。0.2%BSAおよび0.2%Fos−Choline−14を添加したHBST(50mM Hepes、pH7.4、150mM NaCl、0.005%Tween−20)を、両方の泳動用緩衝液として、SDF1α試料の希釈のために使用した。
1.Choma C, Gratkowski H, Lear JD &
DeGrado WF. (2000) Asparagine-mediated self-association of a model
transmembrane helix. Nat Struct Biol 7, 161-6.
2.Slovic AM, Kono H, Lear JD, Saven JG
& DeGrado WF. (2004) Computational design of water-soluble analogues of the
potassium channel KcsA. Proc Natl Acad Sci U SA 101, 1828-33
3.Walters RF & DeGrado WF. (2006)
Helix-packing motifs in membrane proteins. Proc Natl Acad Sci U S A 103,
13658-63
4.Zhang Y, Kulp DW, Lear JD & DeGrado
WF. (2009) Experimental and computational evaluation of forces directing the
association of transmembrane helices. J Am Chem Soc 131, 11341-11343
Claims (16)
- Gタンパク質共役型受容体(GPCR)の水溶性変異体であって、前記変異体において、親水性面に面している前記GPCRのα−ヘリックス位置b、c、及びfであって、位置a、d、e、及びgではない位置で、7回膜貫通α−へリックスの疎水性残基のロイシン(L)、イソロイシン(I)、バリン(V)、及びフェニルアラニン(F)が、グルタミン(Q)、スレオニン(T)、スレオニン(T)、及びチロシン(Y)によってそれぞれ置換されている、変異体。
- 前記GPCRの生物活性を有する、請求項1に記載の変異体。
- 前記生物活性はリガンド結合である、請求項2に記載の変異体。
- 前記変異体は前記GPCRの前記リガンド結合の活性のうち少なくとも幾つかを保持する、請求項3に記載の変異体。
- 前記変異体のpIは前記GPCRのpIと実質的に同一である、請求項1〜4のいずれか1項に記載の変異体。
- 前記変異体の他の部分において追加的な保存的変異のあることを更に含む、請求項1〜4のいずれか1項に記載の変異体。
- 前記GPCRが哺乳類受容体である、請求項1〜6のいずれか1項に記載の変異体。
- 前記GPCRが、プリン受容体(P2Y1、P2Y2、P2Y4、P2Y6)、M1およびM3ムスカリン性アセチルコリン受容体、トロンビンに対する受容体[プロテアーゼ活性化受容体(PAR)−1、PAR−2]、トロンボキサン(TXA2)、スフィンゴシン−1−リン酸(S1P2、S1P3、S1P4およびS1P5)、リゾホスファチジン酸(LPA1、LPA2、LPA3)、アンジオテンシンII(AT1)、セロトニン(5−HT2cおよび5−HT4)、ソマトスタチン(sst5)、エンドセリン(ETAおよびETB)、コレシストキニン(CCK1)、V1aバソプレシン受容体、D5ドパミン受容体、fMLPホルミルペプチド受容体、GAL2ガラニン受容体、EP3プロスタノイド受容体、A1アデノシン受容体、α1アドレナリン受容体、BB2ボンベシン受容体、B2ブラジキニン受容体、カルシウム感知受容体、ケモカイン受容体、KSHV−ORF74ケモカイン受容体、NK1タキキニン受容体、甲状腺刺激ホルモン(TSH)受容体、プロテアーゼ活性化受容体、神経ペプチド受容体、アデノシンA2B受容体、P2Yプリン受容体、代謝グルタミン酸受容体、GRK5、GPCR−30、およびC−X−Cケモカイン受容体型4(CXCR4)からなる群から選択される、請求項1〜7のいずれか1項に記載の変異体。
- 前記GPCRはC−X−Cケモカイン受容体型4(CXCR4)である、請求項1〜7のいずれか1項に記載の変異体。
- 少なくとも1つの膜貫通領域が配列番号3,4,5,6又は8を有する、請求項1に記載の変異体。
- 前記GPCRの活性により媒介される障害又は疾患に罹患した哺乳類の治療用医薬製造での、請求項1〜10のいずれか1項に記載の前記水溶性変異体の使用。
- 請求項1〜10のいずれか1項に記載の有効量の前記変異体及び薬学的に許容可能な希釈剤又は担体を含む医薬組成物。
- Gタンパク質共役型受容体(GPCR)の水溶性変異体の調整法であって、
親水性面に面している前記GPCRのα−ヘリックス位置b、c、及びfであって、位置a、d、e、及びgではない位置で、7回膜貫通α−へリックスの疎水性残基のロイシン(L)、イソロイシン(I)、バリン(V)、及びフェニルアラニン(F)をグルタミン(Q)、スレオニン(T)、スレオニン(T)、及びチロシン(Y)によってそれぞれ置換することを含む、調整法。 - リガンド結合を測定することを更に含む、請求項13に記載の調整法。
- 前記GPCRは無細胞系を使用して調整されることを特徴とする、請求項13又は14に記載の調整法。
- 請求項1〜10のいずれか1項に記載の変異体を発現させるためのトランスフェクトされた細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161445740P | 2011-02-23 | 2011-02-23 | |
US61/445,740 | 2011-02-23 | ||
PCT/US2012/026353 WO2012116203A1 (en) | 2011-02-23 | 2012-02-23 | Water soluble membrane proteins and methods for the preparation and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014508763A JP2014508763A (ja) | 2014-04-10 |
JP2014508763A5 JP2014508763A5 (ja) | 2015-04-09 |
JP6263773B2 true JP6263773B2 (ja) | 2018-01-24 |
Family
ID=46721234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013555565A Active JP6263773B2 (ja) | 2011-02-23 | 2012-02-23 | 水溶性膜タンパク質およびその調製および使用方法 |
Country Status (14)
Country | Link |
---|---|
US (4) | US8637452B2 (ja) |
EP (1) | EP2709647B1 (ja) |
JP (1) | JP6263773B2 (ja) |
KR (1) | KR101963914B1 (ja) |
CN (2) | CN108752461A (ja) |
AU (3) | AU2012220558A1 (ja) |
BR (1) | BR112013020969A2 (ja) |
CA (1) | CA2827187C (ja) |
CL (1) | CL2013002419A1 (ja) |
EA (1) | EA201391041A1 (ja) |
IL (2) | IL227886A0 (ja) |
MX (1) | MX347038B (ja) |
SG (2) | SG10201701547VA (ja) |
WO (1) | WO2012116203A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116203A1 (en) | 2011-02-23 | 2012-08-30 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
US9700521B2 (en) | 2013-03-14 | 2017-07-11 | Massachusetts Institute Of Technology | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies |
WO2014176544A1 (en) * | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Water soluble g-protein coupled receptor |
WO2014176524A2 (en) | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
WO2015149085A2 (en) | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
WO2015148820A1 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
GB2527286A (en) | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
WO2016025781A1 (en) | 2014-08-15 | 2016-02-18 | Cornell University | Compositions and methods for making water-soluble integral membrane proteins |
CN104198689A (zh) * | 2014-08-25 | 2014-12-10 | 李洁 | 一种检测g-蛋白耦联受体对缩血管物质反应的方法 |
JP7061461B2 (ja) * | 2015-02-18 | 2022-04-28 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜貫通タンパク質ならびにその調製および使用方法 |
CN104946674B (zh) * | 2015-06-17 | 2018-05-01 | 山东大学 | 一种腺苷三磷酸/双磷酸酶及其编码基因与应用 |
CN106749602A (zh) * | 2016-12-30 | 2017-05-31 | 武汉金开瑞生物工程有限公司 | 一种助表达序列及其在无细胞表达adcy2蛋白中的应用 |
WO2019046699A1 (en) | 2017-09-01 | 2019-03-07 | Massachustetts Institute Of Technology | NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF |
WO2019117057A1 (ja) * | 2017-12-11 | 2019-06-20 | アステラス製薬株式会社 | 細胞膜透過性ペプチド |
CN108245686B (zh) * | 2018-01-15 | 2019-08-13 | 中国科学院昆明动物研究所 | 人grk5基因的用途 |
US11555060B2 (en) * | 2020-03-25 | 2023-01-17 | Avalon GloboCare Corp. | QTY FC fusion water soluble receptor proteins |
WO2021202186A2 (en) | 2020-03-31 | 2021-10-07 | Massachusetts Institute Of Technology | Qty fc fusion receptor proteins |
US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US544021A (en) * | 1895-08-06 | William k | ||
NZ260103A (en) | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin with alterations in the alpha-helix-1 region |
US5739273A (en) * | 1992-02-12 | 1998-04-14 | Yale University | Transmembrane polypeptide and methods of use |
JPH09278793A (ja) * | 1996-04-10 | 1997-10-28 | Kinichiro Miura | ポリペプチド |
US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
CA2372164A1 (en) * | 1999-03-11 | 2000-09-14 | Gerd G. Kochendoerfer | Chemical synthesis and use of soluble membrane protein receptor domains |
AU3695801A (en) | 2000-02-11 | 2001-11-20 | Amgen, Inc. | Receptor from tnf family |
US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
CA2517848A1 (en) | 2003-01-21 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa |
DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
EP1789452B1 (en) | 2004-08-25 | 2012-04-25 | Janssen Pharmaceutica NV | Relaxin-chimeric polypeptides and their preparation and use |
ATE540970T1 (de) * | 2005-02-08 | 2012-01-15 | Res Dev Foundation | Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs) |
BRPI0502759B1 (pt) * | 2005-06-30 | 2014-02-25 | óleo lubrificante e composição lubrificante para uma máquina de refrigeração | |
WO2007089899A2 (en) * | 2006-02-01 | 2007-08-09 | Oklahoma Medical Research Foundation | Water-soluble (g protein)-coupled receptor protein |
ES2529261T3 (es) | 2006-06-09 | 2015-02-18 | Novartis Ag | Polipéptidos estabilizados del factor de crecimiento similares a insulina |
GB2456236B8 (en) | 2007-03-22 | 2009-12-09 | Heptares Therapeutics Ltd | Stable muscarinic receptor mutants |
WO2008143910A2 (en) * | 2007-05-18 | 2008-11-27 | University Of Massachusetts | A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins |
GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
WO2008068534A2 (en) | 2008-03-05 | 2008-06-12 | Heptares Therapeutics Limited | Crystal structure of a betal -adremergi c receptor and uses thereof |
GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
WO2012098413A1 (en) | 2011-01-21 | 2012-07-26 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
WO2012116203A1 (en) | 2011-02-23 | 2012-08-30 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
US20130273585A1 (en) | 2012-04-11 | 2013-10-17 | Gangagen, Inc. | Soluble cytoplasmic expression of heterologous proteins in escherichia coli |
WO2015148820A1 (en) | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
-
2012
- 2012-02-23 WO PCT/US2012/026353 patent/WO2012116203A1/en active Application Filing
- 2012-02-23 CN CN201810684571.XA patent/CN108752461A/zh active Pending
- 2012-02-23 JP JP2013555565A patent/JP6263773B2/ja active Active
- 2012-02-23 AU AU2012220558A patent/AU2012220558A1/en not_active Abandoned
- 2012-02-23 MX MX2013009715A patent/MX347038B/es active IP Right Grant
- 2012-02-23 CA CA2827187A patent/CA2827187C/en not_active Expired - Fee Related
- 2012-02-23 CN CN2012800096906A patent/CN103458915A/zh active Pending
- 2012-02-23 SG SG10201701547VA patent/SG10201701547VA/en unknown
- 2012-02-23 KR KR1020137024789A patent/KR101963914B1/ko active IP Right Grant
- 2012-02-23 EP EP12750085.8A patent/EP2709647B1/en active Active
- 2012-02-23 US US13/403,725 patent/US8637452B2/en active Active
- 2012-02-23 SG SG2013059811A patent/SG192646A1/en unknown
- 2012-02-23 EA EA201391041A patent/EA201391041A1/ru unknown
- 2012-02-23 BR BR112013020969A patent/BR112013020969A2/pt not_active Application Discontinuation
-
2013
- 2013-08-08 IL IL227886A patent/IL227886A0/en active IP Right Grant
- 2013-08-21 CL CL2013002419A patent/CL2013002419A1/es unknown
- 2013-12-13 US US14/105,252 patent/US9309302B2/en active Active
-
2016
- 2016-03-23 US US15/078,036 patent/US10035837B2/en active Active
- 2016-03-29 AU AU2016201914A patent/AU2016201914A1/en not_active Abandoned
-
2017
- 2017-11-15 AU AU2017261525A patent/AU2017261525A1/en not_active Abandoned
-
2018
- 2018-07-13 US US16/034,549 patent/US20180312562A1/en not_active Abandoned
- 2018-08-14 IL IL261151A patent/IL261151A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR101963914B1 (ko) | 2019-03-29 |
KR20140027117A (ko) | 2014-03-06 |
CN108752461A (zh) | 2018-11-06 |
US20120252719A1 (en) | 2012-10-04 |
EP2709647A1 (en) | 2014-03-26 |
US8637452B2 (en) | 2014-01-28 |
SG192646A1 (en) | 2013-09-30 |
US20160264640A1 (en) | 2016-09-15 |
MX2013009715A (es) | 2014-02-28 |
US20180312562A1 (en) | 2018-11-01 |
EA201391041A1 (ru) | 2014-04-30 |
CN103458915A (zh) | 2013-12-18 |
AU2017261525A1 (en) | 2017-12-07 |
MX347038B (es) | 2017-04-10 |
CL2013002419A1 (es) | 2014-06-06 |
CA2827187C (en) | 2019-01-08 |
EP2709647A4 (en) | 2015-01-21 |
US20140243277A1 (en) | 2014-08-28 |
SG10201701547VA (en) | 2017-03-30 |
JP2014508763A (ja) | 2014-04-10 |
IL227886A0 (en) | 2013-09-30 |
WO2012116203A1 (en) | 2012-08-30 |
US10035837B2 (en) | 2018-07-31 |
US9309302B2 (en) | 2016-04-12 |
CA2827187A1 (en) | 2012-08-30 |
AU2012220558A1 (en) | 2013-08-22 |
BR112013020969A2 (pt) | 2018-07-10 |
EP2709647B1 (en) | 2019-08-07 |
IL261151A (en) | 2018-10-31 |
AU2016201914A1 (en) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6263773B2 (ja) | 水溶性膜タンパク質およびその調製および使用方法 | |
TWI685501B (zh) | 金屬蛋白酶第三型(timp-3)之組織抑制劑之變體、組合物及方法 | |
JP3868494B2 (ja) | オピオイドアンタゴニストおよびそれらの使用方法 | |
CA2586344C (en) | G protein coupled receptor agonists and antagonists and methods of use | |
US9346871B2 (en) | Engineered CXCL12 alpha locked dimer polypeptide | |
US7863416B2 (en) | Nociceptin-based analgesics | |
US20090252705A1 (en) | IL-6/IL-6R Fusion Protein | |
Zachariassen et al. | Probing the molecular interactions between CXC chemokine receptor 4 (CXCR4) and an arginine-based tripeptidomimetic antagonist (KRH-1636) | |
US20180118806A1 (en) | Engineered replacement of partial variant water soluble membrane proteins | |
Ohlstein et al. | Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist | |
JP2003510248A (ja) | ケモカイン受容体ccr3アンタゴニスト | |
US20020064770A1 (en) | Binding compounds and methods for identifying binding compounds | |
US20220153792A1 (en) | Peptide Inhibitors Targeting The CXCL12/HMGB1 Interaction And Uses Thereof | |
AU2001247674A1 (en) | Binding compounds and methods for identifying binding compounds | |
WO2004058189A2 (en) | Chemokine antagonists and uses thereof | |
CN114258317A (zh) | 用于治疗炎性病症的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170602 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6263773 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |